Table 2 Comparison of the training group and validation group.
Training group | Validation group | ||
|---|---|---|---|
Number of patients | 384 | 174 | p-value |
Age at diagnosis | 0.203 | ||
< 50 years | 251 (65.4) | 104 (59.8) | |
≥ 50 years | 133 (34.6) | 70 (40.2) | |
Tumor grade | 0.849 | ||
G1/2 | 313 (81.5) | 143 (82.2) | |
G3 | 71 (18.5) | 31 (17.8) | |
Estrogen receptor | 0.698 | ||
Negative | 76 (19.7) | 32 (18.4) | |
Positive | 308 (80.3) | 142 (81.6) | |
Progesterone receptor | 0.475 | ||
Negative | 125 (32.6) | 62 (35.6) | |
Positive | 259 (67.4) | 112 (64.4) | |
HER2 status | 0.545 | ||
Negative | 298 (77.6) | 139 (79.9) | |
Positive | 86 (22.4) | 35 (20.1) | |
Biological subtype | 0.359 | ||
HR+/HER2− | 260 (67.7) | 119 (68.4) | |
HR+/HER2+ | 49 (12.8) | 23 (13.2) | |
HR−/HER2+ | 35 (9.1) | 9 (5.2) | |
HR−/HER2− | 40 (10.4) | 23 (13.2) | |
Clinical T stage | 0.051 | ||
T1 | 32 (8.4) | 22 (12.6) | |
T2 | 245 (63.8) | 109 (62.6) | |
T3 | 95 (24.7) | 43 (24.8) | |
T4 | 12 (3.1) | 0 | |
Clinical N stage | 0.032 | ||
N0 | 70 (18.2) | 22 (12.6) | |
N1 | 286 (74.5) | 129 (74.2) | |
N2 | 28 (7.3) | 23 (16.2) | |
Surgery type | 0.309 | ||
Breast conserving surgery | 172 (44.8) | 86 (49.4) | |
Total mastectomy | 212 (55.2) | 88 (50.6) | |
Number of positive SLN(s) | 0.608 | ||
1 | 190 (49.5) | 94 (54.0) | |
2 | 144 (37.5) | 59 (33.9) | |
3 | 50 (13.0) | 21 (12.1) | |
Residual nodal disease | 0.942 | ||
Absent | 215 (56.0) | 98 (56.3) | |
Present | 169 (44.0) | 76 (43.7) | |
Mean Invasion Depth in SLN (mm) | 5.3 (0.3–30) | 5.7 (0.3–23) | 0.294 |
Response to NAC | 0.128 | ||
Complete remission | 18 (4.7) | 4 (2.3) | |
Partial remission (≥ 30% reduction) | 269 (70.1) | 137 (78.7) | |
Stable disease | 90 (23.4) | 29 (16.7) | |
Progressive disease | 7 (1.8) | 4 (2.3) |
